Anupam Verma, MD

Speciality:

Language(s):

  • English, Hindi, Gujarati

Location(s):

Dr. Anupam Verma is a pediatric hematologist-oncologist at Pediatric Specialists of Virginia’s (PSV) Center for Cancer and Blood Disorders (CCBD), specializing in pediatric and young adult acute leukemias, including high-risk and relapsed/refractory cases, as well as leukemia in children with Down syndrome. She is also interested in clinical trial development and inherited bone marrow failure syndromes. Board certified in pediatrics and pediatric hematology-oncology, Dr. Verma completed her fellowship at the University of Utah in 2012. She has contributed to multiple publications on childhood leukemia and related topics.

Dr. Verma grew up in Gujarat, India, and developed an interest in medicine after encountering a teenager with acute myeloid leukemia during her pediatric rotation. Her goal is to improve survival outcomes for children and young adults with leukemia. Recently relocated from Salt Lake City, Utah, Dr. Verma enjoys the diversity of the Washington, DC area. Outside of work, she enjoys hiking, cooking, watching movies, and practicing yoga. She also volunteers at her daughter’s high school on the diversity, equity, and inclusion board. Dr. Verma’s proudest accomplishment is being a part of her patients’ cancer journeys, providing care and support to families during challenging times.

Publications: 

Survival Outcomes of Children with Relapsed or Refractory Myeloid Leukemia Associated with Down syndrome (ML-DS). Blood Adv. 2023 Feb. PMID: 36735769

Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study. Leukemia. 2023 May. PMID: 36813993

Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia. Infect Control Hosp Epidemiol. 2022. PMID: 35465865

Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia. Blood Lymphat Cancer, 2021. P MCID: PMC8064615

PEGylated E. Coli Asparaginase Desensitization: An Effective and Feasible Option for Pediatric Patients with Acute Lymphoblastic Leukemia Who Have Developed Hypersensitivity to Pegaspargase in the Absence of Asparaginase Erwinia Chrysanthemi Availability. Pediatr Hematol Oncol, 2019.

Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. JAMA Network Open, 2021.

Kids-DOTT Trial Investigators and the ATLAS Group. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA. 2022. PMID: 35015038

Board Certifications:

  • American Board of Pediatrics, American Board of Pediatric - Hematology Oncology

Education:

  • Fellowship: Pediatric Hematology Oncology, University of Utah, Salt Lake City, UT (2012)

    • Chief Resident: Pediatrics, Brookdale University Hospital Medical Center, Brooklyn, NY (2005)

      • Residency: Pediatrics, Brookdale University Hospital Medical Center, Brooklyn, NY (2005)

        • Residency: Pediatrics, All India Institute of Medical Science, New Delhi, India (2002)

          • Residency: Pediatrics, M S University of Baroda Medical College, India (2000)

            • Medical School: M S University of Baroda Medical College, India (1996)